SCHEMBL22493354

SCHEMBL22493354

Cc1cnccc1CCNC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 2/20 0.37
▸ HRH3 Q9Y5N1 2/20 0.37
▸ AOC1 P19801 7/20 0.35
▸ AOC3 Q16853 7/20 0.35
▸ LATS1 O95835 1/20 0.35
▸ LATS2 Q9NRM7 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ OPRL1 P41146 2/20 0.33
▸ GPR119 Q8TDV5 1/20 0.32
▸ MTNR1A P48039 1/20 0.32
▸ NOTUM Q6P988 1/20 0.32
▸ PRKCH P24723 1/20 0.32
▸ PRKCE Q02156 1/20 0.32
▸ PRKCQ Q04759 1/20 0.32
▸ PRKCD Q05655 1/20 0.32
▸ ADAMTS4 O75173 1/20 0.31
▸ SLC40A1 Q9NP59 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22493240 0.79 LATS1 (0.39) HRH4HRH3AOC1AOC3LATS1
SCHEMBL27290290 0.74 GPR119 (0.35) AOC1AOC3KDM4EALDH1A1MAPT
SCHEMBL873728 0.74 CYP2E1 (0.49) AOC1AOC3LATS1
SCHEMBL6628774 0.72 TKT (0.39) AOC1AOC3KDM4EALDH1A1GPR119
SCHEMBL14945019 0.72 TAAR1 (0.52) AOC1AOC3
SCHEMBL12870192 0.72 AOC1 (0.36) AOC1AOC3LATS1LATS2KDM4E
SCHEMBL10245322 0.72 SMN1; SMN2 (0.47) ALDH1A1
SCHEMBL18924363 0.71 TDP1 (0.43) HRH3AOC1AOC3KDM4EALDH1A1
SCHEMBL21983945 0.71 TAAR1 (0.50) KDM4EALDH1A1NOTUM
SCHEMBL2733403 0.70 CHRNA7 (0.52) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137506-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. (US) 2024-06-27 — — WO disclosed
WO-2023225021-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) CURASEN THERAPEUTICS, INC. (US) 2023-11-23 — — WO disclosed
WO-2020198466-A9 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020198466-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-10-01 — — WO disclosed
Send feedback